Lab

Lifesciences & Healthcare

United Kingdom

Discovery, innovation, market awareness and understanding are key to those lifesciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.
Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Lifesciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

Read more Read less

"A one-stop-shop for us: its remarkable and successful mix of talent makes it sound out from the rest, and makes our lives much easier."

Chambers UK, 2015

Choose area

    Biotech

    Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market. As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

    Read more

    Devices & Diagnostics

    In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovative and reliable medical technologies and services. Devices and diagnostics are subject to complex regulatory and compliance frameworks and are often subject to competitive tendering so you will need lawyers who can reliably advise on pragmatic, compliant solutions.

    Read more

    eHealth

    With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations look  to consistently push boundaries to bring products and services to both the consumer and professional market. However, the regulation of ehealth solutions, devices and services is often outpaced by the novelty and innovation in the solutions themselves and at CMS, we understand the challenges this presents.

    Read more

    Healthcare

    The healthcare sector in the UK and internationally continues to experience a period of dynamic change underpinned by significant legal reforms and devolution to the four British nations. As an owner, operator or service provider in this sector, you are facing a highly regulated environment combined with increased public scrutiny. With increasing opportunities for the private provision of healthcare along with an ageing population, but with shrinking public healthcare budgets, operating within the healthcare sector presents both challenges and opportunities.

    Read more

    Pharmaceuticals

    With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

    Read more
    High­lights of our ex­per­i­ence in Lifes­ci­ences in the...
    Law-Now: Lifes­ci­ences
    Vis­it Law-Now for leg­al know-how and com­ment­ary

    Feed

    Show only
    1 May 2017
    CMS, Nabarro and Olswang com­plete largest ever mer­ger...
    Cre­at­ing a new fu­ture-fa­cing firm
    07 Nov 17
    Save the Date: Dy­nam­ic Mar­kets and Vir­tu­al Risks
    CMS Glob­al Lifes­ci­ences For­um 2017
    28/07/2017
    No priv­ilege against em­ploy­er over per­son­al doc­u­ments on em­ploy­er’s...
    A prop­erty de­vel­op­ment com­pany has suc­cess­fully res­isted an ap­plic­a­tion by its former Group Fin­ance Dir­ect­or to re­strain use of per­son­al doc­u­ments on the grounds of leg­al pro­fes­sion­al priv­ilege. The High Court held that the dir­ect­or was not able to as­sert priv­ilege.
    21 March 2017
    Olswang ad­vises two new VC cli­ents on Series B in­vest­ment...
    20/07/2017
    Entry in­to force of EU Clin­ic­al Tri­als Reg­u­la­tion post­poned to 2019
    On 16 June 2017, the European Medi­cines Agency (“EMA”) pub­lished a press re­lease1 an­noun­cing the post­pone­ment of the entry in­to force of the EU Clin­ic­al Tri­als Reg­u­la­tion of 16 April 2016. 2 It was one of the top­ics at the June 2017 meet­ing of the EMA Man­age­ment.
    7 March 2017
    Olswang ad­vises IP sup­port ser­vices busi­ness RWS Hold­ings...
    07/07/2017
    Im­port­ant les­sons on ex­cess­ive pri­cing: the CMA pub­lishes its full...
    On 15 June 2017, the Com­pet­i­tion & Mar­kets Au­thor­ity (CMA) pub­lished the full non-con­fid­en­tial text of its in­fringe­ment de­cision in a case con­cern­ing phar­ma­ceut­ic­al man­u­fac­turer Pf­izer Lim­ited and its dis­trib­ut­or Flynn Pharma Lim­ited (Pf­izer and Flynn).
    14 February 2017
    Health Tech 2017: a case for great­er con­nec­tion
    07/07/2017
    Im­port­ant les­sons on ex­cess­ive pri­cing: the CMA pub­lishes its full...
    On 15 June 2017, the Com­pet­i­tion & Mar­kets Au­thor­ity (CMA) pub­lished the full non-con­fid­en­tial text of its in­fringe­ment de­cision in a case con­cern­ing phar­ma­ceut­ic­al man­u­fac­turer Pf­izer Lim­ited and its dis­trib­ut­or Flynn Pharma Lim­ited (Pf­izer and Flynn).
    13 December 2016
    CMS, Nabarro and Olswang con­firm Prac­tice and Sec­tor...
    23/06/2017
    European Com­mis­sion in­vest­ig­ates po­ten­tial ex­cess­ive pri­cing of life-sav­ing...
    On 15 May 2017, the European Com­mis­sion opened a form­al in­vest­ig­a­tion in­to the pri­cing of medi­cines. [1] The Com­mis­sion is in­vest­ig­at­ing wheth­er As­pen Pharma has been im­pos­ing ex­cess­ive pri­cing that con­sti­tutes an ab­use of dom­in­ant po­s­i­tion in vi­ol­a­tion of European.
    11 November 2016
    12 Olswang part­ners re­cog­nised as Band 1 in Cham­bers...
    23/06/2017
    Brexit one year on: The Uni­fied Pat­ent Court
    The Uni­fied Pat­ent Court (“UPC”) has been edging closer to real­ity in re­cent years and the UK was set to play a ma­jor role. The UPC aims to provide an easi­er and more cost-ef­fect­ive way to pro­tect and ex­ploit pat­ent rights in Europe, and pat­ents in the life.
    Benjamin Hendry
    10 October 2016
    CMS, Nabarro and Olswang com­bine to cre­ate 6th largest...
    22/06/2017
    The Court of Justice of the EU held that the Bel­gian gen­er­al pro­hib­i­tion...
    On 4 May 2017, the Court of Justice of the EU answered sev­er­al pre­ju­di­cial ques­tions sub­mit­ted by the Bel­gian tribunal of first in­stance re­gard­ing the ad­vert­ising of the ser­vices of dent­ists. In this judg­ment, the Court held that the Bel­gian le­gis­la­tion im­pos­ing.
    10 October 2016
    CMS, Nabarro and Olswang com­bine to cre­ate 6th largest...
    21/06/2017
    The Ver­dict - Round-up of cor­por­ate crime de­vel­op­ments across CMS
    We are pleased to send our new is­sue of The Ver­dict, an at-a-glance round-up of re­cent leg­al de­vel­op­ments in re­la­tion to cor­por­ate crime. In this is­sue, the spot­light is on some sig­ni­fic­ant changes to anti-cor­rup­tion laws in the Czech Re­pub­lic, in­clud­ing.
    15 September 2016
    Olswang's status as a lead­ing TMT firm again ac­know­ledged...